US 11,685,728 B2
Capsid inhibitors for the prevention of HIV
Elena Bekerman, Castro Valley, CA (US); Wade S. Blair, Poolesville, MD (US); Anna Chiu, Burlingame, CA (US); Tomas Cihlar, Burlingame, CA (US); Dana J. Levine, San Leandro, CA (US); Winston C. Tse, Redwood City, CA (US); Stephen R. Yant, Boulder Creek, CA (US); and Jim X. Zheng, Foster City, CA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Nov. 25, 2020, as Appl. No. 17/104,554.
Claims priority of provisional application 63/028,804, filed on May 22, 2020.
Claims priority of provisional application 62/940,535, filed on Nov. 26, 2019.
Prior Publication US 2021/0188815 A1, Jun. 24, 2021
Int. Cl. C07D 401/14 (2006.01); A61P 31/18 (2006.01); A61K 45/06 (2006.01)
CPC C07D 401/14 (2013.01) [A61K 45/06 (2013.01); A61P 31/18 (2018.01); C07B 2200/13 (2013.01)] 69 Claims
 
1. A method of preventing an HIV infection in a subject, comprising administering to the subject a compound of Formula (Ia) or Formula (Ib):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
the compound of Formula (Ia) or Formula (Ib), or a pharmaceutically acceptable salt thereof, is administered subcutaneously at a concentration of about 309 mg/mL; or
the compound of Formula (Ia) or Formula (Ib), or a pharmaceutically acceptable salt thereof, is administered intramuscularly at a concentration of about 400 mg/mL to about 500 mg/mL; or
the compound of Formula (Ia) or Formula (Ib), or a pharmaceutically acceptable salt thereof, is administered subcutaneously at a concentration of about 400 mg/mL; or
the compound of Formula (Ia) or Formula (Ib), or a pharmaceutically acceptable salt thereof, is administered subcutaneously at a concentration of about 500 mg/mL.